Form 4: DiaMedica Therapeutics CEO Granted 600,000 Stock Options, Aligning Executive Incentives

DiaMedica Therapeutics Inc.'s President and CEO, Pauls Dietrich John, was granted 600,000 stock options at an exercise price of $4.11, aligning executive incentives with shareholder value.

Summary

• Pauls Dietrich John, President & CEO and Director of DiaMedica Therapeutics Inc. (DMAC), acquired 600,000 stock options on June 1, 2025.
• These options have an exercise price of $4.11 per share and are set to expire on May 31, 2035.
• The options will vest with respect to 25% of the underlying common shares on June 1, 2026, with the remaining 75% vesting quarterly over the subsequent three years, commencing September 1, 2026.
• Following this transaction, Mr. John directly beneficially owns 600,000 derivative securities (stock options) and 68,591 voting common shares.
• The reported common shares include 1,749 shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating alignment of interests and potential for future growth, though it carries the inherent potential for dilution upon exercise.

Positives

• The grant of 600,000 stock options to the President & CEO aligns management's long-term interests with those of shareholders, as the options gain value only if the stock price increases above the exercise price of $4.11.
• The significant size of the option grant indicates a commitment to the company's future performance by a key executive.

Negatives

• The issuance of new stock options, if exercised, could lead to dilution of existing shareholders' equity, although this is a common practice for executive compensation.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with shareholder value; potential for future dilution if options are exercised.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation strategies.

Next Steps

• Vesting of 25% of stock options on June 1, 2026.
• Quarterly vesting of the remaining 75% of stock options over the following three years, commencing September 1, 2026.

Key Dates

Recommendation

Keywords

DiaMedica Therapeutics, DMAC, SEC Form 4, Insider Transaction, Stock Options, Executive Compensation, Pauls Dietrich John, CEO, Director, Equity Grant, Beneficial Ownership